iloprost

Pre-clinicalWithdrawn

1 views this week 0 watching💤 Quiet

Interest: 15/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Persistent Pulmonary Hypertension

Conditions

Persistent Pulmonary Hypertension, Respiratory Distress Syndrome

Trial Timeline

May 1, 2006 → Oct 1, 2008

NCT ID

NCT00216931

About iloprost

iloprost is a pre-clinical stage product being developed by Bayer for Persistent Pulmonary Hypertension. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00216931. Target conditions include Persistent Pulmonary Hypertension, Respiratory Distress Syndrome.

What happened to similar drugs?

4 of 8 similar drugs in Persistent Pulmonary Hypertension were approved

Approved (4) Terminated (1) Active (4)

✅Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved

✅RivastigmineNovartisApproved

✅Omalizumab + PlaceboNovartisApproved

✅irbesartan + placeboSanofiApproved

🔄E7777 9 mcg/kgEisaiPhase 3

🔄CertoparinNovartisPhase 3

🔄Omalizumab + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01054105	Pre-clinical	Completed	Oct 1, 2010	Dec 25, 2018	Pulmonary Arterial Hypertension
NCT00216931	Pre-clinical	Withdrawn	May 1, 2006	Oct 1, 2008	Persistent Pulmonary Hypertension

Competing Products

20 competing products in Persistent Pulmonary Hypertension

See all competitors

Product	Company	Stage	Hype Score
E7777 9 mcg/kg	Eisai	Phase 3	40
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution	Santen Pharmaceutical	Phase 2	35
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E	AstraZeneca	Phase 1	29
AZD0837 + VKA INR 2-3	AstraZeneca	Phase 2	35
AZD0837 + Aspirin	AstraZeneca	Phase 2	35
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	26
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone Acetate	Novartis	Phase 2	35
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + Placebo	Novartis	Approved	35
Certoparin	Novartis	Phase 3	40
Omalizumab + Placebo	Novartis	Phase 3	40
Rivastigmine	Novartis	Approved	43
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days	Novartis	Phase 2	35
Indacaterol + Placebo to Indacaterol	Novartis	Phase 2	35
Omalizumab + Placebo	Novartis	Approved	43
placebo + iv sildenafil	Pfizer	Phase 3	40
etanercept + placebo	Pfizer	Phase 2	35
Sildenafil	Pfizer	Phase 2	27
irbesartan + placebo	Sanofi	Approved	39
IV Remodulin + Placebo	United Therapeutics	Phase 2	24
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)	Glaukos	Phase 2	24